Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Strong Trial Results, Effective Distribution Could Put Regeneron’s Praluent ‘Back In The Competition’

Courtesy of Benzinga.

Strong Trial Results, Effective Distribution Could Put Regeneron's Praluent 'Back In The Competition'

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)’s promising Praluent trial outcomes — and an effective marketing strategy to expand access to the drug — could give the company a strong competitive standing in the cardiovascular drug market, according to Bank of America Merrill Lynch.

The Analyst

BofA’s Ying Huang maintained a Buy rating and $520 price target on Regeneron.

The Thesis

Top-line data from the Odyssey Outcomes Cardiovascular Outcomes trial demonstrated that treatment with Praluent offered a 15-percent reduction in heart attacks, ischemic strokes, hospitalization from angina and coronary heart disease death, Huang said in a Sunday note. 

The reduction in all-cause mortality is likely to “put Praluent back in the competition,” the analyst said.

“We believe both physicians and payers will take this mortality benefit in consideration.”

Regeneron announced a plan to reduce the net price of the cholesterol drug to payers willing to reduce access barriers to high-risk patients, which will likely expand the distribution of Praluent, Huang said. 

“While this may reduce the addressable patient population, we believe this strategy will make the drug ultimately more accessible.”

Price Action

At the time of publication, Regeneron Pharmaceuticals shares were trading up 0.57 percent at $343.64.

Related Links:

The Week Ahead In Biotech: Earnings, PDUFA Dates And More

7 Biotech Stocks With Clinical Trial Outcomes In March

Latest Ratings for REGN

Date Firm Action From To
Feb 2018 Canaccord Genuity Downgrades Buy Hold
Feb 2018 BMO Capital Maintains Market Perform Market Perform
Feb 2018 Morgan Stanley Maintains Equal-Weight Equal-Weight

View More Analyst Ratings for REGN


View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Health Care Price Target Reiteration Top Stories Analyst Ratings General Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!